Related Experiment Video
Updated: May 5, 2026
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
Unwanted disorders and xenogeneic graft-versus-host disease in experimental immunodeficient mice: How to evaluate and
Seyed Mostafa Monzavi1, Samad Muhammadnejad1,2, Vahid Mansouri1
1Gene Therapy Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Human-derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient-derived or cell line-derived xenograft tumors, is dependent on immunodeficient strains. Tumor-bearing immunodeficient mice are susceptible to developing unwanted disorders primarily irrelevant to the tumor nature; and if get involved with such disorders, reliability of the study results will be undermined, inevitably confounding the research in general. Therefore, a rigorous health surveillance and clinical monitoring system, along with the establishment of a strictly controlled barrier facility to maintain a pathogen-free state, are mandatory. Even if all pathogen control and biosafety measures are followed, there are various noninfectious disorders capable of causing tissue and multiorgan damage in immunodeficient animals. Therefore, the researchers should be aware of sentinel signs to carefully monitor and impartially report them. This review discusses clinical signs of common unwanted disorders in experimental immunodeficient mice, and how to examine and report them.
Insights
Monitoring immunodeficient mice for health issues is crucial for reliable preclinical cancer drug development. This review details common disorders and reporting methods in these vital research models.
Area of Science:
- Preclinical research
- Animal models
- Oncology
Background:
- Human-derived tumor models (patient-derived xenografts, cell line-derived xenografts) are critical for anticancer drug development.
- Immunodeficient mouse strains are essential for these models but prone to non-tumor-related health issues.
- Such health issues can compromise study reliability and research outcomes.
Purpose of the Study:
- To review common health disorders observed in experimental immunodeficient mice.
- To guide researchers on monitoring, examining, and reporting sentinel signs of these disorders.
- To emphasize the importance of health surveillance for data integrity.
Main Methods:
- Literature review of common disorders in immunodeficient mice.
- Discussion of clinical signs and examination techniques.
- Guidance on impartial reporting of observed health issues.
Main Results:
- Identified common non-tumor-related disorders affecting immunodeficient mice.
- Outlined key clinical signs indicative of these disorders.
- Stressed the need for rigorous health surveillance and controlled environments.
Conclusions:
- Awareness and reporting of sentinel signs in immunodeficient mice are vital for research validity.
- Strict health monitoring and controlled facilities mitigate risks to study reliability.
- Proactive management of animal health ensures robust preclinical drug development.
More Related Videos
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:40Cell-mediated Immune Responses
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...